Clinical Trial

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-03; most recent amendment 2025-12-23.
Trial Details
NCT Number NCT06813365
Lead Sponsor Dizal Pharmaceuticals
Conditions Nonsmall-cell Lung Cancer
Enrollment 190 participants
Start Date 2024-06-12
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-30